Bronchogen
Peptide Bioregulator
Also known as Ala-Glu-Asp-Leu (AEDL)
Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu, a short synthetic peptide of the bioregulator class studied in research on bronchopulmonary tissue models.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu, a short synthetic peptide of the bioregulator class studied in research on bronchopulmonary tissue models.
Experimental work examines short-peptide modulation of gene expression in cultured human cells under controlled conditions.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for the 20mg lot is being finalised and will be published here as soon as the lab returns it.
Bronchogen belongs to the family of short regulatory peptides investigated for tissue-directed activity, in this case in bronchial and lung research models. Studies of the AEDL sequence have examined epigenetic mechanisms, including effects on gene expression during cellular ageing.
The compound is a four-residue peptide, small enough that research has focused on direct peptide-DNA and peptide-chromatin interactions rather than classical receptor pharmacology.
Bronchogen arises from the Russian peptide-bioregulator research programme, which characterized a series of short tissue-directed peptides from the 1980s onward.
Subsequent work placed the AEDL sequence within a broader model of short peptides acting on gene expression and cell differentiation.
Research into the AEDL sequence centers on epigenetic regulation of gene expression in ageing human cell cultures and on peptide-directed cell differentiation. The compound-specific literature is limited relative to better-studied peptides.
3 of the 4 areas below are addressed directly by a paper cited on this page.
Short-peptide epigenetic regulation models
Addressed on this page by Ashapkin 2015, Khavinson 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Ashapkin, VV. et al. (2015) — Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells
- Khavinson, V. et al. (2020) — Peptide Regulation of Cell Differentiation
Bronchopulmonary tissue-culture research
No paper cited on this page reports on bronchopulmonary, tissue or culture. This heading marks where Bronchogen is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Gene-expression and cell-ageing studies
Addressed on this page by Ashapkin 2015, Khavinson 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Ashapkin, VV. et al. (2015) — Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells
- Khavinson, V. et al. (2020) — Peptide Regulation of Cell Differentiation
Peptide-directed differentiation frameworks
Addressed on this page by Khavinson 2020, Ashapkin 2015. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, V. et al. (2020) — Peptide Regulation of Cell Differentiation
- Ashapkin, VV. et al. (2015) — Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells
The references section of this page cites 2 primary papers published between 2015 and 2020 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Bronchogen, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Bronchogen is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under short-peptide epigenetic regulation models, bronchopulmonary tissue-culture research and gene-expression and cell-ageing studies.
The 2 papers cited on this page, published between 2015 and 2020 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented alongside compounds with decades of published research, as though the evidence base is comparable.
It is not. Bronchogen rests on 2 cited papers (between 2015 and 2020). A record that thin cannot support conclusions about mechanism, effect or safety, and the honest reading is that this compound has been studied very little rather than studied and validated.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Bronchogen is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Bronchogen in the United States through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
Bronchogen is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 4 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (20mg / Single Vial, 20mg / 5-Pack, 20mg / 10-Pack available), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of Bronchogen. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99